Kauppila A, Mäkilä U M, Mäkäräinen L, Puolakka J, Seppälä A
Eur J Obstet Gynecol Reprod Biol. 1986 Sep;22(5-6):359-63. doi: 10.1016/0028-2243(86)90126-7.
Thirty-one patients with primary dysmenorrhoea were treated in a double-blind, six-period, cross-over clinical trial with tiaprofenic acid, naproxen sodium and a placebo in randomized order, each for 2 consecutive cycles. Complete disappearance of the symptoms or pronounced therapeutic effects were obtained with tiaprofenic acid, naproxen sodium and the placebo in 74%, 65% and 35% of cases, respectively, while these treatments were ineffective in 3%, 6% and 38% of cases, respectively. Tiaprofenic acid was superior to the placebo for relieving pelvic pain and overall discomfort and for reducing the need for bed-rest. Naproxen sodium compared favourably with the placebo with respect to pelvic pain and overall discomfort. The effects of tiaprofenic acid and naproxen sodium were not significantly different. Tiaprofenic acid had no side-effects, whereas tiredness was experienced in 3 cases of naproxen sodium treatment. The results indicate that tiaprofenic acid is a useful alternative for the treatment of primary dysmenorrhoea.
31例原发性痛经患者参与了一项双盲、六周期、交叉临床试验,按随机顺序分别接受替诺昔康、萘普生钠及安慰剂治疗,各治疗2个连续周期。替诺昔康、萘普生钠及安慰剂分别使74%、65%和35%的患者症状完全消失或获得显著治疗效果,而这些治疗分别对3%、6%和38%的患者无效。在缓解盆腔疼痛、总体不适及减少卧床需求方面,替诺昔康优于安慰剂。在盆腔疼痛和总体不适方面,萘普生钠与安慰剂相比效果良好。替诺昔康和萘普生钠的疗效无显著差异。替诺昔康无副作用,而萘普生钠治疗有3例出现疲倦。结果表明,替诺昔康是治疗原发性痛经的一种有效替代药物。